Victory Capital Management Inc. Sells 1,633 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Victory Capital Management Inc. lowered its stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 0.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 179,570 shares of the company’s stock after selling 1,633 shares during the quarter. Victory Capital Management Inc. owned 0.32% of Ginkgo Bioworks worth $1,463,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Paloma Partners Management Co purchased a new stake in shares of Ginkgo Bioworks in the first quarter valued at $28,000. Algert Global LLC purchased a new stake in shares of Ginkgo Bioworks in the second quarter worth approximately $36,000. Russell Investments Group Ltd. lifted its stake in shares of Ginkgo Bioworks by 9,440.6% during the 1st quarter. Russell Investments Group Ltd. now owns 31,961 shares of the company’s stock worth $37,000 after acquiring an additional 31,626 shares during the last quarter. Wellington Wealth Strategies LLC. purchased a new position in Ginkgo Bioworks during the 2nd quarter valued at $41,000. Finally, Thoroughbred Financial Services LLC purchased a new stake in Ginkgo Bioworks in the second quarter worth $70,000. 78.63% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. TD Cowen upped their price target on shares of Ginkgo Bioworks from $3.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, September 20th. BTIG Research lifted their price target on shares of Ginkgo Bioworks from $0.20 to $7.00 and gave the company a “sell” rating in a research note on Friday, August 23rd. Three research analysts have rated the stock with a sell rating, one has given a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $4.58.

Ginkgo Bioworks Trading Up 13.2 %

NYSE DNA opened at $8.13 on Tuesday. The company has a market capitalization of $467.31 million, a P/E ratio of -0.60 and a beta of 1.09. Ginkgo Bioworks Holdings, Inc. has a 52-week low of $5.26 and a 52-week high of $75.20. The company’s 50 day simple moving average is $7.84.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.